• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview

    5/7/25 4:05:00 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACAD alert in real time by email

    - First quarter total revenues of $244.3 million, up 19% year-over-year

    - First quarter NUPLAZID® (pimavanserin) net product sales of $159.7 million, up 23% year-over-year

    - First quarter DAYBUE® (trofinetide) net product sales of $84.6 million, up 11% year-over-year, and up 9.5% in unique patients shipped

    - Reiterates full year 2025 revenue guidance including DAYBUE net sales of $380 to $405 million and NUPLAZID net sales of $650 to $690 million

    - Accelerated timing for COMPASS PWS Phase 3 study of ACP-101 in Prader Willi Syndrome, topline results now expected in early Q4 2025

    Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced its financial results for the first quarter ended March 31, 2025.

    "2025 is off to a strong start for Acadia, achieving total revenue of $244.3 million in the first quarter," said Catherine Owen Adams, Chief Executive Officer. "DAYBUE has achieved meaningful patient growth for the first time since the second quarter of 2024, serving more patients this quarter than in any prior quarter, and NUPLAZID continues to drive strong momentum from the direct-to-consumer campaign we launched last year. We're continuing to execute on our commitment to expand the DAYBUE franchise globally and recently served the first patient outside the U.S. through our managed access program in the European Union. As we look ahead, we're excited to share that we now expect the topline results from our COMPASS PWS Phase 3 study of ACP-101 early in the fourth quarter of 2025. We are also looking forward to sharing more details about our pipeline programs at our inaugural R&D Day next month."

    Company Updates

    • During the first quarter, the Company reached a record high with 954 unique patients receiving a DAYBUE shipment.
    • In May, the Company completed its planned 30% expansion of the DAYBUE field force to support broader engagement with healthcare professionals that treat Rett syndrome patients.
    • In April, the first shipment of DAYBUE was made to a Rett syndrome patient in the European Union under Acadia's managed access program.
    • As a result of favorable enrollment trends in the COMPASS PWS Phase 3 study of ACP-101 (intranasal carbetocin) in Prader Willi Syndrome, the Company now expects topline results from the study early in the fourth quarter of 2025. If results are positive, the Company anticipates submitting a New Drug Application to the U.S. Food and Drug Administration in the first quarter of 2026.

    Financial Results

    Revenues

    Total revenues comprising of net product sales from NUPLAZID and DAYBUE were $244.3 million, up 19% from the first quarter of 2024.

    Net product sales of NUPLAZID were $159.7 million in the first quarter of 2025, an increase of 23% as compared to $129.9 million for the first quarter of 2024. The 23% year-over-year increase in net product sales of NUPLAZID included 6% volume growth in 2025 compared to 2024 and a seasonal reduction in gross to net from the Medicare Part D redesign as part of the Inflation Reduction Act.

    Net product sales of DAYBUE were $84.6 million for the first quarter of 2025, an increase of 11% as compared to $75.9 million for first quarter of 2024. The increase in net product sales of DAYBUE was primarily due to the growth in unit sales as the Company shipped to more unique patients.

    Research and Development

    Research and development expenses were $78.3 million, compared to $59.7 million for the three months ended March 31, 2025, and 2024, respectively. The increase was mainly due to increased costs from clinical stage programs.

    Selling, General and Administrative

    Selling, general and administrative expenses were $126.4 million and $108.0 million for the three months ended March 31, 2025, and 2024, respectively. The increase for this period was primarily driven by the costs related to the consumer activation program to support the NUPLAZID franchise and higher commercial operation expenses for the planned expansion of the DAYBUE team.

    Net Income

    For the three months ended March 31, 2025, Acadia reported net income of $19.0 million, or $0.11 per common share, compared to net income of $16.6 million, or $0.10 per common share, for the same period in 2024.

    Cash and Investments

    At March 31, 2025, Acadia's cash, cash equivalents and investment securities totaled $681.6 million, compared to $756.0 million at December 31, 2024. While cash flow from operating activities was positive in the first quarter, the Company made total payments to Neuren Pharmaceuticals Limited (Neuren) in the amount of $98.8 million during the quarter related to Neuren's share of the net proceeds from the Company's recent sale of its Rare Pediatric Disease Priority Review Voucher and an annual net sales milestone.

    Full Year 2025 Financial Guidance

    Acadia is reiterating its 2025 guidance that was provided on February 26, 2025 with the exception of R&D expenses:

    • Total Revenues (U.S. only) of $1.03 to $1.095 billion.
    • NUPLAZID net product sales in the range of $650 to $690 million.
    • DAYBUE net product sales (U.S. only) in the range of $380 to $405 million.
    • R&D expense in the range of $330 to $350 million, up from prior guidance range of $310 to $330 million primarily due to the acceleration of the ACP-101 Phase 3 study timeline.
    • SG&A expense in the range of $535 to $565 million.

    Conference Call and Webcast Information

    Acadia will host a conference call to discuss the first quarter 2025 results today, Wednesday, May 7, 2025 at 1:30 p.m. PT/4:30 p.m. ET. The conference call may be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call.

    About NUPLAZID® (pimavanserin)

    Pimavanserin is a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors. These receptors are thought to play an important role in neuropsychiatric disorders. In vitro, pimavanserin demonstrated no appreciable binding affinity for dopamine (including D2), histamine, muscarinic, or adrenergic receptors. Pimavanserin was approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis by the U.S. Food and Drug Administration in April 2016 under the trade name NUPLAZID.

    About DAYBUE® (trofinetide)

    Trofinetide is a synthetic version of a naturally occurring molecule known as the tripeptide glycine-proline-glutamate (GPE). The mechanism by which trofinetide exerts therapeutic effects in patients with Rett syndrome is unknown. Trofinetide was approved for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older by the U.S. Food and Drug Administration in March 2023 under the trade name DAYBUE.

    About Acadia Pharmaceuticals

    Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer's disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at Acadia.com and follow us on LinkedIn and X.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "potential," "continue" and similar expressions (including the negative thereof) intended to identify forward-looking statements. Forward-looking statements contained in this press release, include, but are not limited to, statements about: (i) our business strategy, objectives and opportunities, including support for and innovations in our pipeline assets and business development opportunities, investments in consumer activation, expansion of our DAYBUE sales force in the US, and building of our EU commercial team, and potential for enhanced shareholder value; (ii) plans for, including timing, development and progress of commercialization or regulatory timelines for our products, including NUPLAZID and DAYBUE, and our product candidates; (iii) benefits to be derived from and efficacy of our products, including the potential advantages of our products; (iv) the timing and conduct of and topline results for our clinical trials, including the timing of topline results from our clinical trial in Prader-Willi syndrome, the continuing enrollment in our clinical trials in Alzheimer's disease psychosis, the initiation of our clinical trial in Lewy Body Dementia Psychosis, and the timing and content of our presentations or announcements regarding our clinical trials; (v) our estimates regarding our future financial performance, profitability, capital requirements or expenses, including our full year 2025 financial guidance, and (vi) our ability to successfully complete additional business development transactions. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to: our dependency on the continued successful commercialization of our products and our ability to maintain or increase sales of our products; our plans to commercialize DAYBUE globally and trofinetide in the EU; the costs of our commercialization plans and development programs, and the financial impact or revenues from any commercialization we undertake; our ability to obtain necessary regulatory approvals for our product candidates and, if and when approved, market acceptance of our products; the risks associated with clinical trials and their outcomes, including risks of unsuccessful enrollment and negative or inconsistent results; our dependence on third-party collaborators, clinical research organizations, manufacturers, suppliers and distributors; the impact of competitive products and therapies; our ability to generate or obtain the necessary capital to fund our operations; our ability to grow, equip and train our specialized sales forces; our ability to manage the growth and complexity of our organization; our ability to maintain, protect and enhance our intellectual property; and our ability to continue to stay in compliance with applicable laws and regulations. Given the risks and uncertainties, you should not place undue reliance on these forward-looking statements. For a discussion of these and other risks, uncertainties and other factors that may cause our actual results, performance or achievements to differ, please refer to our annual report on Form 10-K for the year ended December 31, 2024 as well as our subsequent filings with the Securities and Exchange Commission from time to time, including our quarterly report on Form 10-Q for the quarter ended March 31, 2025. The forward-looking statements contained herein are made as of the date hereof, and we undertake no obligation to update them after this date, except as required by law.

    ACADIA PHARMACEUTICALS INC.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (in thousands, except per share amounts)

    (Unaudited)

     

     

    Three Months Ended March 31,

     

     

     

    2025

     

     

    2024

     

    Revenues

     

     

     

     

     

     

    Product sales, net

     

    $

    244,317

     

     

    $

    205,831

     

    Total revenues

     

     

    244,317

     

     

     

    205,831

     

    Operating expenses

     

     

     

     

     

     

    Cost of product sales (1)(2)

     

     

    20,392

     

     

     

    22,951

     

    Research and development (2)

     

     

    78,265

     

     

     

    59,679

     

    Selling, general and administrative (2)

     

     

    126,370

     

     

     

    107,991

     

    Total operating expenses

     

     

    225,027

     

     

     

    190,621

     

    Income from operations

     

     

    19,290

     

     

     

    15,210

     

    Interest income, net

     

     

    7,901

     

     

     

    5,506

     

    Other income

     

     

    588

     

     

     

    286

     

    Income before income taxes

     

     

    27,779

     

     

     

    21,002

     

    Income tax expense

     

     

    8,792

     

     

     

    4,447

     

    Net income

     

    $

    18,987

     

     

    $

    16,555

     

    Earnings per share:

     

     

     

     

     

     

    Basic

     

    $

    0.11

     

     

    $

    0.10

     

    Diluted

     

    $

    0.11

     

     

    $

    0.10

     

    Weighted average common shares outstanding:

     

     

     

     

     

     

    Basic

     

     

    166,808

     

     

     

    164,798

     

    Diluted

     

     

    167,668

     

     

     

    166,623

     

     

     

     

     

     

     

     

    (1) Includes license fees and royalties

     

     

     

     

     

     

     

     

     

     

     

     

     

    (2) Includes the following stock-based compensation expense

     

     

     

     

     

     

     

     

     

     

     

     

     

    Cost of product sales, license fees and royalties

     

    $

    334

     

     

    $

    153

     

    Research and development

     

    $

    3,433

     

     

    $

    4,093

     

    Selling, general and administrative

     

    $

    7,613

     

     

    $

    10,504

     

    ACADIA PHARMACEUTICALS INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (in thousands)

     

     

    March 31,

    2025

     

     

    December 31,

    2024

     

     

     

    (unaudited)

     

     

     

     

    Assets

     

     

     

     

     

     

    Cash, cash equivalents and investment securities

     

    $

    681,577

     

     

    $

    755,993

     

    Accounts receivable, net

     

     

    105,743

     

     

     

    98,739

     

    Interest and other receivables

     

     

    7,971

     

     

     

    5,956

     

    Inventory

     

     

    22,948

     

     

     

    21,949

     

    Prepaid expenses

     

     

    52,703

     

     

     

    55,681

     

    Total current assets

     

     

    870,942

     

     

     

    938,318

     

    Property and equipment, net

     

     

    3,498

     

     

     

    4,215

     

    Operating lease right-of-use assets

     

     

    50,614

     

     

     

    46,571

     

    Intangible assets, net

     

     

    117,060

     

     

     

    119,782

     

    Restricted cash

     

     

    8,770

     

     

     

    8,770

     

    Long-term inventory

     

     

    80,025

     

     

     

    69,741

     

    Other assets

     

     

    1,455

     

     

     

    359

     

    Total assets

     

    $

    1,132,364

     

     

    $

    1,187,756

     

    Liabilities and stockholders' equity

     

     

     

     

     

     

    Accounts payable

     

    $

    18,095

     

     

    $

    16,192

     

    Accrued liabilities

     

     

    284,435

     

     

     

    378,678

     

    Total current liabilities

     

     

    302,530

     

     

     

    394,870

     

    Operating lease liabilities

     

     

    44,634

     

     

     

    42,037

     

    Other long-term liabilities

     

     

    19,963

     

     

     

    18,056

     

    Total liabilities

     

     

    367,127

     

     

     

    454,963

     

    Total stockholders' equity

     

     

    765,237

     

     

     

    732,793

     

    Total liabilities and stockholders' equity

     

    $

    1,132,364

     

     

    $

    1,187,756

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250507955158/en/

    Investor Contact:

    Acadia Pharmaceuticals Inc.

    Al Kildani

    (858) 261-2872

    [email protected]

    Acadia Pharmaceuticals Inc.

    Jessica Tieszen

    (858) 261-2950

    [email protected]

    Media Contact:

    Acadia Pharmaceuticals Inc.

    Deb Kazenelson

    (818) 395-3043

    [email protected]

    Get the next $ACAD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACAD

    DatePrice TargetRatingAnalyst
    2/11/2025$22.00Hold
    Deutsche Bank
    1/3/2025$23.00 → $20.00Buy → Neutral
    Guggenheim
    10/10/2024Mkt Perform
    Raymond James
    8/7/2024$28.00 → $20.00Overweight → Equal-Weight
    Morgan Stanley
    6/27/2024$31.00Outperform
    BMO Capital Markets
    3/12/2024$36.00 → $32.00Buy
    Needham
    3/12/2024$39.00 → $25.00Buy → Neutral
    Mizuho
    1/30/2024$40.00Outperform
    Robert W. Baird
    More analyst ratings

    $ACAD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Deutsche Bank initiated coverage on ACADIA Pharmaceuticals with a new price target

      Deutsche Bank initiated coverage of ACADIA Pharmaceuticals with a rating of Hold and set a new price target of $22.00

      2/11/25 7:00:07 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ACADIA Pharmaceuticals downgraded by Guggenheim with a new price target

      Guggenheim downgraded ACADIA Pharmaceuticals from Buy to Neutral and set a new price target of $20.00 from $23.00 previously

      1/3/25 7:17:06 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James resumed coverage on ACADIA Pharmaceuticals

      Raymond James resumed coverage of ACADIA Pharmaceuticals with a rating of Mkt Perform

      10/10/24 8:39:02 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACAD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRINCIPAL ACCOUNTING OFFICER Kihara James converted options into 2,596 shares and sold $19,374 worth of shares (1,327 units at $14.60), increasing direct ownership by 6% to 23,526 units (SEC Form 4)

      4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)

      5/2/25 8:00:34 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, CHIEF FINANCIAL OFFICER Schneyer Mark C. converted options into 6,815 shares and sold $51,071 worth of shares (3,498 units at $14.60), increasing direct ownership by 6% to 62,773 units (SEC Form 4)

      4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)

      5/2/25 7:59:08 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, CHIEF FINANCIAL OFFICER Schneyer Mark C. converted options into 5,275 shares and sold $40,133 worth of shares (2,708 units at $14.82), increasing direct ownership by 5% to 59,456 units (SEC Form 4)

      4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)

      4/8/25 7:40:13 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACAD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview

      - First quarter total revenues of $244.3 million, up 19% year-over-year - First quarter NUPLAZID® (pimavanserin) net product sales of $159.7 million, up 23% year-over-year - First quarter DAYBUE® (trofinetide) net product sales of $84.6 million, up 11% year-over-year, and up 9.5% in unique patients shipped - Reiterates full year 2025 revenue guidance including DAYBUE net sales of $380 to $405 million and NUPLAZID net sales of $650 to $690 million - Accelerated timing for COMPASS PWS Phase 3 study of ACP-101 in Prader Willi Syndrome, topline results now expected in early Q4 2025 Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced its financial results for the first quarter ended M

      5/7/25 4:05:00 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference

      Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025 at 3:40 p.m. Pacific Time. A live webcast of Acadia's fireside chat will be accessible on the company's website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commerciali

      5/5/25 4:05:00 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025

      Company to host conference call and webcast on Wednesday, May 7, 2025, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report first quarter financial results on Wednesday, May 7, 2025, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on May 7, 2025, at 4:30 p.m. Eastern Time. The webcast will be available on Acadia's website, Acadia.com under the investors section and will be archived there until August 6, 2025. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number and unique PI

      4/23/25 4:05:00 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACAD
    Financials

    Live finance-specific insights

    See more
    • Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview

      - First quarter total revenues of $244.3 million, up 19% year-over-year - First quarter NUPLAZID® (pimavanserin) net product sales of $159.7 million, up 23% year-over-year - First quarter DAYBUE® (trofinetide) net product sales of $84.6 million, up 11% year-over-year, and up 9.5% in unique patients shipped - Reiterates full year 2025 revenue guidance including DAYBUE net sales of $380 to $405 million and NUPLAZID net sales of $650 to $690 million - Accelerated timing for COMPASS PWS Phase 3 study of ACP-101 in Prader Willi Syndrome, topline results now expected in early Q4 2025 Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced its financial results for the first quarter ended M

      5/7/25 4:05:00 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025

      Company to host conference call and webcast on Wednesday, May 7, 2025, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report first quarter financial results on Wednesday, May 7, 2025, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on May 7, 2025, at 4:30 p.m. Eastern Time. The webcast will be available on Acadia's website, Acadia.com under the investors section and will be archived there until August 6, 2025. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number and unique PI

      4/23/25 4:05:00 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

      - 2024 total net product sales of $957.8 million, reflecting 32% revenue growth - Fourth quarter DAYBUE® (trofinetide) net product sales of $96.7 million and full year 2024 net product sales of $348.4 million - Fourth quarter NUPLAZID® (pimavanserin) net product sales of $162.9 million and full year 2024 net product sales of $609.4 million - Full year 2025 total revenue guidance of $1.03 to $1.095 billion including DAYBUE net sales guidance of $380 to $405 million and NUPLAZID net sales guidance of $650 to $690 million Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced its financial results for the fourth quarter and full year ended December 31, 2024. "We closed 2024 on a s

      2/26/25 4:05:00 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACAD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ACADIA Pharmaceuticals Inc.

      SC 13G/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)

      11/14/24 6:48:52 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ACADIA Pharmaceuticals Inc.

      SC 13G - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)

      2/14/24 7:08:13 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ACADIA Pharmaceuticals Inc. (Amendment)

      SC 13G/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)

      2/13/24 4:56:01 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACAD
    SEC Filings

    See more
    • SEC Form 10-Q filed by ACADIA Pharmaceuticals Inc.

      10-Q - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)

      5/7/25 9:15:42 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ACADIA Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)

      5/7/25 4:13:19 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by ACADIA Pharmaceuticals Inc.

      DEF 14A - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)

      4/25/25 4:49:09 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACAD
    Leadership Updates

    Live Leadership Updates

    See more
    • Acadia Pharmaceuticals Set to Join S&P SmallCap 600

      NEW YORK, Dec. 30, 2024 /PRNewswire/ -- Acadia Pharmaceuticals Inc. (NASD: ACAD) will replace Independent Bank Group Inc. (NASD: IBTX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 3, 2025. S&P MidCap 400 constituent SouthState Corp. (NYSE:SSB) is acquiring Independent Bank Group in a deal expected to close soon pending final conditions. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector Jan 3, 2025 S&P SmallCap 600 Addition Acadia Pharmaceuticals ACAD Health Care Jan 3, 2025 S&P SmallCap 600 Deletion Independent Bank Group

      12/30/24 5:37:00 PM ET
      $ACAD
      $IBTX
      $SPGI
      $SSB
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Banks
      Finance
    • Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer

      – Seasoned commercial executive with more than 25 years pharmaceutical and biotech experience Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that Thomas Andrew Garner has been appointed Chief Commercial Officer, effective today. Mr. Garner will spearhead Acadia's commercial strategy and operations, driving the Company's plans for sustained growth and expansion of its product portfolio and pipeline across U.S. and international markets. Mr. Garner will report to Catherine Owen Adams, Acadia's CEO, and serve on the executive leadership team. "Tom is an accomplished commercial executive with a demonstrated history of driving brand growth across a wide range of therapeutic areas

      12/9/24 9:00:00 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals

      - Ms. Owen Adams brings over 25 years of pharmaceutical industry experience including senior commercial leadership roles with Bristol Myers Squibb and Johnson & Johnson Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that Catherine Owen Adams has succeeded Steve Davis as Chief Executive Officer (CEO) and joined the Acadia Board of Directors. "We are excited to welcome Catherine Owen Adams as the new CEO of Acadia," said Stephen Biggar, M.D., Ph.D., Chair of the Board of Directors. "Catherine is a proven global leader with a distinguished record of accomplishment of driving growth and innovation in the pharmaceutical industry. Her strategic vision, deep expertise, and unwavering

      9/23/24 4:15:00 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACAD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

      Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-9) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 210793, Application Classification: Efficacy

      9/18/23 10:47:05 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

      Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-12) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 207318, Application Classification: Efficacy

      9/18/23 10:40:05 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for DAYBUE issued to ACADIA PHARMS INC

      Submission status for ACADIA PHARMS INC's drug DAYBUE (ORIG-1) with active ingredient TROFINETIDE has changed to 'Approval' on 03/10/2023. Application Category: NDA, Application Number: 217026, Application Classification: Type 1 - New Molecular Entity

      3/13/23 10:37:07 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care